Polysaccharide biological response modifiers. 2006

M Y K Leung, and C Liu, and J C M Koon, and K P Fung
Institute of Chinese Medicine, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, People's Republic of China.

Biological response modifiers (BRMs) are substances which augment immune response. BRMs can be cytokines which are produced endogenously in our body by immune cells or derivatives of bacteria, fungi, brown algae, Aloe vera and photosynthetic plants. Such exogeneous derivatives (exogeneous BRMs) can be nucleic acid (CpG), lipid (lipotechoic acid), protein or polysaccharide in nature. The receptors for these exogeneous BRMs are pattern recognition receptors. The binding of exogeneous BRMs to pattern recognition receptors triggers immune response. Exogenous BRMs have been reported to have anti-viral, anti-bacterial, anti-fungal, anti-parasitic, and anti-tumor activities. Among different exogeneous BRMs, polysaccharide BRMs have the widest occurrence in nature. Some polysaccharide BRMs have been tested for their therapeutic properties in human clinical trials. An overview of current understandings of polysaccharide BRMs is summarized in this review.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D011134 Polysaccharides Long chain polymeric CARBOHYDRATES composed of MONOSACCHARIDES linked by glycosidic bonds. Glycan,Glycans,Polysaccharide
D011971 Receptors, Immunologic Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behavior of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere. Immunologic Receptors,Immunologic Receptor,Immunological Receptors,Receptor, Immunologic,Receptors, Immunological
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

M Y K Leung, and C Liu, and J C M Koon, and K P Fung
January 1994, Cancer chemotherapy and biological response modifiers,
M Y K Leung, and C Liu, and J C M Koon, and K P Fung
May 1983, Journal of the National Cancer Institute,
M Y K Leung, and C Liu, and J C M Koon, and K P Fung
January 1996, Cancer chemotherapy and biological response modifiers,
M Y K Leung, and C Liu, and J C M Koon, and K P Fung
June 1986, Seminars in oncology,
M Y K Leung, and C Liu, and J C M Koon, and K P Fung
January 1995, European journal of cancer (Oxford, England : 1990),
M Y K Leung, and C Liu, and J C M Koon, and K P Fung
April 1995, Lung cancer (Amsterdam, Netherlands),
M Y K Leung, and C Liu, and J C M Koon, and K P Fung
January 1999, Cancer chemotherapy and biological response modifiers,
M Y K Leung, and C Liu, and J C M Koon, and K P Fung
January 1992, Cancer chemotherapy and biological response modifiers,
M Y K Leung, and C Liu, and J C M Koon, and K P Fung
January 1993, Cancer chemotherapy and biological response modifiers,
M Y K Leung, and C Liu, and J C M Koon, and K P Fung
January 1988, Cancer chemotherapy and biological response modifiers,
Copied contents to your clipboard!